Litcius/Paper detail

An experimental and computational study of pyrimidine based bis-uracil derivatives as efficient candidates for optical, nonlinear optical, and drug discovery applications

Bharti Mohan, Mukesh Choudhary, Gaurav Kumar, Shabbir Muhammad, Neeladri Das, Khushwant Singh, Abdullah G. Al‐Sehemi, Santosh Kumar

2020Synthetic Communications25 citationsDOI

Abstract

Three novel pyrimidine based bis-uracil derivatives 1–3 were synthesized by the condensation reaction of 2-hydroxynaphthaldehyde with 6-amino-1,3-dimethylpyrimidine-2,-4(1H, 3H)-dione; 6-amino-1, 3-diethylpyrimidine-2,-4(1H, 3H)-dione, and 6-amino-1,-ethyl-3-methylpyrimidine-2,-4(1H, 3H)-dione, respectively and structurally characterized. The preliminary test of compounds was evaluated by SwissADME that can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavors. Antimicrobial, photoluminescence, and molecular docking of compounds were also studied. The kinetic and thermal stabilities along with intramolecular charge transfer characters were obtained for compounds using frontier molecular orbitals, electrostatic potential diagrams as well as their orbital energies. Additionally, we applied state-of-art computational methods to assess the linear and nonlinear optical (NLO) properties of compounds at M06/6-311G** levels of theory. The third-order NLO properties of 1–3 were observed larger as compared to the standard indicating the considerable NLO character of all molecules, which may render the above derivatives as efficient candidates for NLO device fabrications.

Topics & Concepts

ChemistryPyrimidineUracilNonlinear opticalDrug discoveryCombinatorial chemistryNonlinear systemNanotechnologyStereochemistryDNABiochemistryQuantum mechanicsPhysicsMaterials scienceNonlinear Optical Materials ResearchSynthesis and biological activityCancer therapeutics and mechanisms
An experimental and computational study of pyrimidine based bis-uracil derivatives as efficient candidates for optical, nonlinear optical, and drug discovery applications | Litcius